You are here

A point-of-care device for phenylalanine determination

Award Information
Agency: Department of Health and Human Services
Branch: N/A
Contract: 1R43GM126593-01A1
Agency Tracking Number: R43GM126593
Amount: $224,700.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: 300
Solicitation Number: PA17-302
Timeline
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-04-01
Award End Date (Contract End Date): 2019-03-31
Small Business Information
8 ABINGTON RD, Mount Laurel, NJ, 08054-4719
DUNS: 078783141
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Principal Investigator
 ROBERT HARPER
 (856) 343-5098
 invitrodiagnosticsolutions@gmail.com
Business Contact
 ROBERT HARPER
Phone: (856) 343-5098
Email: invitrodiagnosticsolutions@gmail.com
Research Institution
N/A
Abstract
Abstract In Vitro Diagnostic SolutionsIVDSproposes to develop the only point of carePOCtest for the determination of L phenylalaninePhefrom a finger or heel stick sampleThe point of care testthePKU Nowwill be used as a home monitoring device for PKU patients and for diagnostic testing in developing regionsThe PKU Now will provide immediate feedback of whole blood phe concentrationallowing for stricter dietary complianceimprove the quality of lifeand reduce healthcare costsIn Phase I studieswe will resolve three outstanding issues before commercializing the systemnamely eliminating interferencesAimeliminating hematocrit bias in the range oftoAimand establishing agreement between thePKU Nowand a laboratory reference methodAimPhenylketonuriacommonly known as PKUis an inherited disorder that increases the levels of a substance called phenylalanine in the bloodPKU is the most common disorder of amino acid metabolismeffectinginpeoplegloballyMost cases of PKU are detected shortly after birth by newborn screeningIndividuals affected by PKU must monitor and control phe levels throughout their lives to avoid neurological complications includingpermanent intellectual disabilitiesseizuresdelayed developmentbehavioral problemsand psychiatric disordersWhole blood is collected in EDTA tubes or spotted onto Dried Blood SpotDBSCards by parentspatients or caregiversThese samples are sent to laboratories for measurement by tandem mass spec and results can take days to weeksThis complicated process for monitoring and controlling phe levelsresults in non compliancea decrease in quality of lifeas well as increased healthcare costs for treating complicationsThe PKU Now will provide real time phe levelsallowing parents and caregivers to promptly adjust their diets to help maintain optimal phenylalanine levelsIn Vitro Diagnostic SystemsIVDShas developed a prototype POC testin which phe can be quantified from amicroliters of sampleUpon successful validation ofPKU NowPhase II will ensure linearity and precisionestablish intra day and inter day precisionand evaluate preclinical data against tandem mass spec analysisall following CLSI guidelinesPKU Nowwill be the only point of care testing devicePOCTthat will allow the accurate measurement of L phenylalaninephelevels from a finger or heel stick Project Narrative PKU is the most common disorder of amino acid metabolismeffectinginpeoplegloballyWithout proper monitoring and treatmentthese patients can develop permanent intellectual disabilitiesseizuresdelayed developmentbehavioral problemsand psychiatric disordersIVDS propose the development of the PKU Now as a home monitoring point of care device and as well a diagnostic device in developing regions where new born screening is not available

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government